GI Motility Program, Division of Gastroenterology, Cedars-Sinai Medical Center, 8730 Alden Drive, Suite 225E, Los Angeles, CA 90048, USA.
Dig Dis Sci. 2011 Jul;56(7):1962-6. doi: 10.1007/s10620-010-1548-z. Epub 2011 Jan 11.
A recent post-infectious rat model with Campylobacter jejuni 81-176 has replicated the events noted in humans with post-infectious irritable bowel syndrome (IBS). In this study, we test whether prophylactic treatment with the antibiotic rifaximin will prevent the development of long-term altered bowel function in this model.
Sprague-Dawley rats were divided into two groups. Both groups were gavaged with a 1 mL solution of 10(8) cfu/mL of C. jejuni. However, one group was also prophylactically gavaged with a solution of rifaximin 200 mg per day for 3 days (the day before gavage, the day of gavage, and the day after gavage with C. jejuni). Fresh stool was collected from rats daily until two consecutive stool cultures were negative for C. jejuni. The rats were then housed for 3 months. At the end of 3 months, fresh stool was collected on three consecutive days to determine stool % wet weight and stool consistency on a stool score.
Rats that received rifaximin antibiotic prophylaxis had a greater rate of stool shedding of C. jejuni. However, the mean duration of colonization was shorter in the rifaximin-treated group (10.3 ± 7.1 days) compared to rats receiving no prophylaxis (12.6 ± 5.9 days) (P < 0.01). After 3 months, rats that did not receive rifaximin had a greater variability in stool % wet weight (P < 0.01). Furthermore, the average stool consistency over 3 days of measurement was closer to normal in the rifaximin-treated rats, with a consistency of 1.1 ± 0.3, compared to 1.5 ± 0.4 in rats receiving no prophylaxis (P < 0.00001).
Prophylactic treatment of rats with the antibiotic rifaximin in a new animal model of post-infectious IBS with C. jejuni mitigated the development of long-term altered stool form and function.
最近的一项空肠弯曲菌 81-176 感染后大鼠模型复制了人类感染后肠易激综合征（IBS）的相关事件。在这项研究中，我们测试了预防性使用抗生素利福昔明是否会预防该模型中长期改变的肠道功能。
将 Sprague-Dawley 大鼠分为两组。两组均给予 1 mL 浓度为 10(8) cfu/mL 的空肠弯曲菌溶液灌胃。然而，其中一组还预防性地给予利福昔明 200mg/天，连续 3 天（在空肠弯曲菌灌胃前、灌胃当天和灌胃后）。每天从大鼠收集新鲜粪便，直到连续两次粪便培养为空肠弯曲菌阴性。然后将大鼠饲养 3 个月。3 个月结束时，连续 3 天收集新鲜粪便，以确定粪便湿重%和粪便评分的粪便稠度。
接受利福昔明抗生素预防治疗的大鼠空肠弯曲菌粪便脱落率更高。然而，利福昔明治疗组的平均定植时间更短（10.3±7.1 天），而未接受预防治疗的大鼠（12.6±5.9 天）（P<0.01）。3 个月后，未接受利福昔明治疗的大鼠粪便湿重%的变异性更大（P<0.01）。此外，利福昔明治疗组大鼠的平均粪便稠度在 3 天的测量中更接近正常，为 1.1±0.3，而未接受预防治疗的大鼠为 1.5±0.4（P<0.00001）。
在空肠弯曲菌感染后 IBS 的新型动物模型中，预防性使用抗生素利福昔明治疗大鼠减轻了长期改变的粪便形态和功能的发展。
